Evaluation of the clinical utility of ultrasensitive C-peptide assay with glucagon stimulation test in Type 1 diabetic patients

Evaluation of the clinical utility of ultrasensitive C-peptide assay with glucagon stimulation test in Type 1 diabetic patients - Evaluation of the clinical utility of ultrasensitive C-peptide assay with glucagon stimulation test in Type 1 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010575

Enrollment

Registered

2013-04-25

Start date

2013-04-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes

Interventions

Ultrasensitive C-peptide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)subjcets whose age are more than 20 years (2)no restriction on gender (3)written informed consent was obtained from all subjects after they had been provided with sufficient information about the study

Exclusion criteria

Exclusion criteria: (1)Patients with serious liver or renal insufficiency (2)Patients with remarkable metabolic disorder (3)Judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Variability of glucose daily profile by using Continuous Glucose Monitoring System and Self Monitoring Blood Glucose	—

Countries

Japan

Contacts

Public ContactFuki Ikeda

Juntendo University Graduate School of Medicine Dept. of Metabolism and Endocrinology

fuki@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026